Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RHOC | P08134 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.43 |
| ▸ | GCG | P01275 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847010 | 0.93 | GCG (0.47) | CNR1CNR2GCGRGCGHPGD | |
| SCHEMBL4500127 | 0.81 | CYP19A1 (0.44) | MAPTMALT1SMN1; SMN2LMNACCR1 | |
| SCHEMBL5273519 | 0.79 | SMN1; SMN2 (0.43) | GCGKMT2ASMN1; SMN2MCHR1 | |
| SCHEMBL2841580 | 0.76 | CNR1 (0.47) | CNR1CNR2GCGR | |
| SCHEMBL3550717 | 0.76 | MAPT (0.44) | CNR1CNR2MAPTRHOCRHOA | |
| SCHEMBL2843519 | 0.76 | RAB9A (0.53) | CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2844359 | 0.75 | RAB9A (0.54) | CNR1CNR2HPGDSMN1; SMN2EPHX2 | |
| SCHEMBL4508036 | 0.75 | KDM1A (0.46) | MAPTHPGDKDM4EPPARGSMN1; SMN2 | |
| SCHEMBL2846311 | 0.74 | CNR1 (0.45) | CNR1CNR2MALT1HPGDEPHX2 | |
| SCHEMBL2846413 | 0.74 | CNR1 (0.42) | CNR1CNR2GCGRMALT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | claimed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | claimed |
| EP-1858872-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-11-28 | — | — | EP | claimed |
| WO-2006084975-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-08-17 | — | — | WO | claimed |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | disclosed |
| EP-1858872-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006084975-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MAPT 3072/4885 |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MAPT 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.